Danaher (FRA:DAP) Cash Conversion Cycle: 87.03 (As of Mar. 2026)


FRA:DAP Danaher Corp FRA:DAP
72 GF Score
Price €169.05
GF Value €204.24
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Danaher Cash Conversion Cycle?

Danaher FRA:DAP -1.20% 72 Cash Conversion Cycle is 87.03 as of Mar. 2026. GuruFocus rates FRA:DAP with a GF Score™ of 72/100 and a GF Value™ of €204.24 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Danaher's Days Sales Outstanding for the three months ended in Mar. 2026 was 58.9.
Danaher's Days Inventory for the three months ended in Mar. 2026 was 97.93.
Danaher's Days Payable for the three months ended in Mar. 2026 was 69.8.
Therefore, Danaher's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2026 was 87.03.


Danaher  (FRA:DAP) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Danaher Cash Conversion Cycle Related Terms


Danaher Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Danaher's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danaher Cash Conversion Cycle Chart

Danaher Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.80 76.95 94.88 81.72 81.89

Danaher Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.64 90.71 90.93 76.81 87.03

FRA:DAP vs TMO, IDXX, A: Cash Conversion Cycle Comparison

For the Diagnostics & Research subindustry, Danaher's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher Cash Conversion Cycle vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Danaher's Cash Conversion Cycle falls into.


FRA:DAP
72GF Score
Danaher Corp FRA:DAP
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danaher Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Danaher's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=58.45+92.56-69.12
=81.89

Danaher's Cash Conversion Cycle for the quarter that ended in Mar. 2026 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=58.9+97.93-69.8
=87.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 87.03 mean?
Danaher (FRA:DAP) has a Cash Conversion Cycle of 87.03 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Danaher and its competitors.
Is Danaher's Cash Conversion Cycle too high?
Danaher's current Cash Conversion Cycle is 87.03. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 74.74. Danaher's value of 87.03 is 16.4% above this industry median. Overall, Danaher has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Danaher's Cash Conversion Cycle compare to TMO and IDXX?
Danaher's Cash Conversion Cycle of 87.03 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 74.74. Danaher's value of 87.03 is 16.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 74.74, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Danaher's current Cash Conversion Cycle of 87.03 is 16.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Danaher and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danaher's current Cash Conversion Cycle is 87.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Based on GuruFocus' analysis, Danaher (FRA:DAP) is currently considered Modestly Undervalued. The stock's GF Value™ is €204.24, compared to a current price of €169.05 — trading 17.2% below its estimated fair value. The current Cash Conversion Cycle is 87.03 and 16.4% above the Medical Diagnostics & Research industry median of 74.74. Danaher's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Danaher (FRA:DAP), the current Cash Conversion Cycle is 87.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Danaher (FRA:DAP) Overvalued in 2026?

Based on GuruFocus' analysis, Danaher stock appears to be undervalued. The current stock price of €169.05 is trading 17.2% below its estimated GF Value™ of €204.24. GuruFocus considers Danaher to be Modestly Undervalued.

Key valuation signals for FRA:DAP:

  • Cash Conversion Cycle: 87.03
  • GF Value™: €204.24 vs. price of €169.05 (17.2% below fair value)
  • GF Score™: 72/100 with 4 warning signs
  • Industry Position: 16.4% above the Medical Diagnostics & Research median

No single metric tells the full story. See the FRA:DAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Danaher Business Description

Address 2200 Pennsylvania Avenue, NW, Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
72GF Score

Get the complete analysis for FRA:DAP

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€169.05
Price
€204.24
GF Value